523 related articles for article (PubMed ID: 37507595)
41. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
42. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
43. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
44. Triple inhaled therapy for chronic obstructive pulmonary disease.
Montuschi P; Malerba M; Macis G; Mores N; Santini G
Drug Discov Today; 2016 Nov; 21(11):1820-1827. PubMed ID: 27452453
[TBL] [Abstract][Full Text] [Related]
45. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
46. Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.
de Nigris E; Treharne C; Brighton N; Holmgren U; Walker A; Haughney J
Int J Chron Obstruct Pulmon Dis; 2022; 17():2987-3000. PubMed ID: 36444374
[TBL] [Abstract][Full Text] [Related]
47. Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis.
Lee HW; Park J; Jang EJ; Lee CH
Respir Res; 2020 Nov; 21(1):310. PubMed ID: 33238986
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
Quint JK; Montonen J; Esposito DB; He X; Koerner L; Wallace L; de la Hoz A; Miravitlles M
Adv Ther; 2021 May; 38(5):2249-2270. PubMed ID: 33721209
[TBL] [Abstract][Full Text] [Related]
49. New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology.
D'Urzo AD; Cazzola M; Hanania NA; Buhl R; Maleki-Yazdi MR
Int J Chron Obstruct Pulmon Dis; 2018; 13():2805-2819. PubMed ID: 30233171
[TBL] [Abstract][Full Text] [Related]
50. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Chong J; Karner C; Poole P
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
[TBL] [Abstract][Full Text] [Related]
51. The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
Sousa AR; Riley JH; Church A; Zhu CQ; Punekar YS; Fahy WA
NPJ Prim Care Respir Med; 2016 Jun; 26():16031. PubMed ID: 27334739
[TBL] [Abstract][Full Text] [Related]
52. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis.
Horita N; Miyazawa N; Tomaru K; Inoue M; Kaneko T
Respirology; 2015 Nov; 20(8):1153-9. PubMed ID: 26235837
[TBL] [Abstract][Full Text] [Related]
53. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis.
Tricco AC; Strifler L; Veroniki AA; Yazdi F; Khan PA; Scott A; Ng C; Antony J; Mrklas K; D'Souza J; Cardoso R; Straus SE
BMJ Open; 2015 Oct; 5(10):e009183. PubMed ID: 26503392
[TBL] [Abstract][Full Text] [Related]
54. An update on LAMA/LABA combinations for COPD.
Drug Ther Bull; 2017 Jan; 55(1):2-5. PubMed ID: 28057707
[TBL] [Abstract][Full Text] [Related]
55. A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid.
Miravitlles M; Verhamme K; Calverley PMA; Dreher M; Bayer V; Gardev A; de la Hoz A; Wedzicha J; Price D
Int J Chron Obstruct Pulmon Dis; 2022; 17():545-558. PubMed ID: 35309285
[TBL] [Abstract][Full Text] [Related]
56. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma.
Kew KM; Evans DJ; Allison DE; Boyter AC
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011438. PubMed ID: 26031392
[TBL] [Abstract][Full Text] [Related]
57. Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score.
Rogliani P; Ora J; Cavalli F; Cazzola M; Calzetta L
J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956108
[TBL] [Abstract][Full Text] [Related]
58. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.
Rogliani P; Matera MG; Ora J; Cazzola M; Calzetta L
Int J Chron Obstruct Pulmon Dis; 2017; 12():3469-3485. PubMed ID: 29255354
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.
Banerji D; Mahler DA; Hanania NA
Expert Rev Respir Med; 2016 Jul; 10(7):767-80. PubMed ID: 27223863
[TBL] [Abstract][Full Text] [Related]
60. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
Singh D; Fabbri LM; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2019; 14():531-546. PubMed ID: 30880943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
